Core Viewpoint - The announcement highlights the agreement between HeartLink Medical and MicroPort Cardiac Rhythm Management for a business integration, aiming to enhance their strategic positioning in the global cardiovascular market [1][2]. Group 1: Transaction Details - HeartLink Medical plans to acquire 100% of MicroPort Cardiac Rhythm Management for a valuation of $680 million, through a directed share issuance at a price of HKD 1.35 per share [1]. - The acquisition will be executed by issuing new shares to existing shareholders of MicroPort Cardiac Rhythm Management, including its parent company MicroPort Medical and investment firms such as Hillhouse Capital and Yunfeng Capital [1]. Group 2: Business Integration and Strategic Goals - The integration aims to combine the core businesses of cardiac rhythm management and structural heart disease, creating a more comprehensive cardiovascular treatment solution [2]. - The transaction is expected to generate synergies that will diversify and enhance HeartLink Medical's existing business, particularly in structural heart disease and CRM solutions, while improving R&D capabilities, production capacity, distribution channels, and market expansion [1][2]. Group 3: Conditions for Completion - The final implementation of the integration is subject to several closing conditions, including approval from HeartLink Medical's independent shareholders [3].

Core Viewpoint - Company plans to acquire MicroPort Cardiac Rhythm Management for a total consideration of 680 million USD, enhancing its global cardiac product platform [1] Group 1: Acquisition Details - The acquisition will involve the issuance of approximately 3.95 billion new shares at an issue price of 1.35 HKD per share [1] - MicroPort Cardiac Rhythm Management specializes in solutions for arrhythmia management, providing devices to monitor cardiac information [1] Group 2: Strategic Implications - The acquisition is expected to create significant synergies by integrating resources in R&D, production, and sales, thereby strengthening the company's global competitiveness in cardiac treatment [1] - Post-acquisition, the target group will become a wholly-owned subsidiary of the company, with its financial performance consolidated into the company's results [1] Group 3: Shareholder Impact - The transaction requires approval from a special shareholder meeting and other conditions to be met [1] - MicroPort Medical, the controlling shareholder, currently holds approximately 46.12% of the company and will see its stake reduced to about 44.45% post-transaction, remaining the largest shareholder [1]

目标集团主要从事CRM业务，专注于管理心律失常的解决方案。其提供监测患者心脏资讯的设备，以 便识别异常的心脏状况，如心动过缓及快速性心律失常;以及应用电脉冲和电击来预防或治疗有关异常 状况或提供心脏再同步化治疗。 董事认为，交易符合本集团业务的战略发展，将有助于本集团建立具备全球影响力的心脏病产品平台， 以提供多元化产品及产品管线，并实现互补协同效应。交易所产生的有关协同效应将扩大及多元化本集 团现有业务，尤其是强化本集团在结构性心脏病及CRM解决方案的产品及管线，同时提升研发能力、 生产能力、分销渠道及市场扩张能力。 根据合并协议的条款及条件以及遵照开曼《公司法》，本公司将以合并方式收购目标公司，合并附属公 司及目标公司将于生效时间合并并作为一家公司存续，且目标公司于合并后作为本公司的间接全资附属 公司存续，作为代价，本公司将向目标公司股东配发及发行新股份。于合并完成后，目标集团的成员公 司将成为本公司的间接附属公司，且目标集团的财务业绩将并入本集团的财务业绩。 目标公司协定价值为6.8亿美元，乃由本公司与目标公司经参考仲量联行企业评估及谘询有限公司进行 的估值后公平磋商厘定。 心通医疗-B(02160)发 ...